usdaed

Regulatory filings indicate that FCPM III Services B.V. increased its stake in RAPT Therapeutics during the fourth quarter. The aggregate value of these newly acquired shares was estimated at $46.24 million, calculated using the average unadjusted closing price for the period. As of quarter-end, the total value of the position had increased to $53.22 million, reflecting both the trading activity and the concurrent appreciation in RAPT’s share price.

The question before us, then, is this: will this member of the “Magnificent Seven” reach the lofty heights of five hundred dollars a share? A perfectly reasonable inquiry, one might think. Let’s have a bit of a rummage around and see what sort of shenanigans would be required to make such a thing happen over the next five years. It’s a bit like arranging a particularly complicated garden party, really.

Indeed, the Model Y accounts for over seventy percent of Tesla’s vehicle sales. But the seasons turn, and a new contender approaches. Next month, Rivian’s R2 SUV is poised to enter the fray. The question for the discerning investor is not one of alarm, but of measured assessment. How much should those who have placed their faith in Tesla truly fear? And how much should those who see promise in Rivian allow themselves to hope? The answer, I suspect, is more nuanced than the headlines would suggest.

Kynam Capital Management, a firm known for its patient hand and its tolerance for the improbable, recently adjusted its holdings in Cogent (COGT 3.50%), shedding 1,720,949 shares in a transaction valued at approximately $48.38 million. The act itself wasn’t remarkable, these things happen with the rhythm of a hummingbird’s wings. It was the why that held a certain poetry. Kynam, it seems, had simply pruned a particularly exuberant branch, ensuring the tree wouldn’t topple under its own weight. The overall portfolio saw a shift of $105.74 million, a figure that both reflects the trimming and acknowledges the stock’s relentless ascent.

Okay, so everyone’s fixated on the weight-loss drugs. And rightly so. It’s a booming market, and Eli Lilly is, for the moment, leading the charge. There will be competition, obviously. There always is. But they’ve got a head start, and they’re not resting on their laurels. Orforglipron, an oral GLP-1… sounds like something out of a sci-fi film, doesn’t it? But apparently, it’s a game-changer. The fact that it’s an oral medication is… significant. People are less keen on injections, generally. It’s a convenience thing, but it matters. They’re learning from Wegovy, which, let’s be honest, isn’t exactly subtle.

On March 2nd, our Ms. Whalen parted ways with 26,667 shares of Bristow stock, realizing approximately $1.25 million. A sum sufficient to procure a modest principality, or, more realistically, a comfortable retirement in Boca Raton. However, as always, the devil resides not in the headline number, but in the footnotes. It seems a portion of this disbursement was, shall we say, pre-ordained.

The filing with the Securities and Exchange Commission – a document as thrilling as a well-indexed catalogue, naturally – reveals a shedding of 2,957,386 shares during the last quarter. A substantial sum, certainly, but consider it a refinement, not a retreat. The value of the Viridian position diminished by $49.79 million, a consequence of both the market’s whims and the fund’s calculated repositioning. To be overly exposed, my dear reader, is to invite boredom – and potentially, a rather unpleasant reckoning.

For years, Uber’s advertising arm was basically an afterthought. Help a few restaurants get noticed within the Uber Eats app. A nice little earner, sure, but hardly world-changing. They thought it would plateau at around 2% of gross bookings. Honestly, it felt like they were just hoping it would cover the cost of the free ketchup packets. But, plot twist, it’s already exceeded that 2% mark – over $2 billion in annualized revenue – and now they’re admitting it’s… bigger. Much bigger. Which, in corporate speak, translates to: “We have absolutely no idea what we’ve stumbled into.”

But it’s not the past that’s particularly interesting, is it? It’s the present, and the rather peculiar signals Mr. Buffett appears to have been sending with his final acts as CEO. Signals that, when decoded, suggest a distinct lack of enthusiasm for the current state of… well, everything. And the primary method of communication? A truly staggering pile of cash. Specifically, $373 billion. (That’s a lot of pennies. If you laid them end-to-end, they’d probably circle the Earth several times, assuming you had a sufficiently motivated team of penny-layers and a planet willing to cooperate.)